Retrophin Revenue and Competitors

Claim your profile

Location

$317.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Retrophin's estimated annual revenue is currently $11.6M per year.(i)
  • Retrophin received $149.5M in venture funding in March 2015.
  • 0
  • Retrophin's total funding is $317.5M.

Employee Data

    00
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$27.4M177-14%$160MN/A
#2
$3.7M24N/AN/AN/A
#3
$18.1M117-4%$24.1MN/A
#4
$47.1M304-3%N/AN/A
#5
$48.1M310-7%$403MN/A
#6
$459.2M206854%$242.6MN/A
#7
$0.9M650%$6.1MN/A
#8
$14.9M96-17%$140MN/A
#9
$29M187-1%N/AN/A
#10
$3.7M24N/AN/AN/A

We are a biopharmaceutical company (RTRX) dedicated to identifying, developing and delivering life-changing therapies to people living with rare diseases. With our promising pipeline, commercial portfolio and more than 180 team members worldwide, we are a thriving and patient-centric company striving to become a leader in the rare disease community. Giving patients a chance and providing hope is what drives us. Our number one priority will always be the patients we serve. Our approach centers on our pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including a joint development arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to neurological and behavioral impairment. Our R&D efforts are supported by growing revenues from our portfolio of three commercial products. Thank you for visiting our LinkedIn profile. Please read our community guidelines to understand how we manage our social media engagement: retrophin.com/community-guidelines

keywords:Biotechnology, Healthcare

$317.5M

Total Funding

N/A

Number of Employees

$11.6M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Retrophin News

2012-05-07 - Retrophin Completes $4M Series A Financing

Retrophin, LLC, a New York-based, biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases, has completed its $4m Series A financing. The round was led by MSMB Capital, with participation from several current and former senior executives at g ...

09/03/2019 - Retrophin Sinks as Drug “Pharma Bro” Martin Shkreli Co ...

[Corrected, 8/23/19, see below] Retrophin, the drug developer founded by jailed former biotech executive Martin Shkreli, has failed its first big ...

09/08/2019 - Retrophin Announces Topline Results from Phase 3 FORT ...

Retrophin will host a conference call and webcast today, Thursday, August 22, 2019 at 8:30 a.m. ET to discuss the FORT Study results.

09/03/2019 - Why Retrophin, Inc. Is Tanking Today

Shares of the orphan drug specialist Retrophin (NASDAQ:RTRX) are down by 25.3% as of 12:44 p.m. EDT today. The culprit? Retrophin's ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$18M0N/A$168.6M
#2
$22.7M0N/AN/A
#3
$8.4M0N/AN/A
#4
$11.7M0N/A$4.4M
#5
$36.4M0N/A$799M

Retrophin Funding

DateAmountRoundLead InvestorsReference
2012-05-08$4.0MAMSMB CapitalArticle
2013-08-19$25.0MUndisclosedStifelArticle
2014-01-13$40.0MUndisclosedJefferies LLCArticle
2014-06-02$80.0MUndisclosedBarclaysArticle
2014-07-03$91.0MUndisclosedAthyrium Capital ManagementArticle
2015-03-20$149.5MUndisclosedArticle